Zoltán Salló

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 89 citations · Full text

Inflammation, Anti-inflammatory, Immunology +7

Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study

Axel Bauer, Mathias Klemm, Konstantinos D. Rizas et al. · The Lancet · 2019 · 64 citations · Full text

Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation

Nándor Szegedi, Gábor Széplaki, Szilvia Herczeg et al. · EP Europace · 2019 · 49 citations · Full text

The role of local impedance drop in the acute lesion efficacy during pulmonary vein isolation performed with a new contact force sensing catheter—A pilot study

Nándor Szegedi, Zoltán Salló, Péter Perge et al. · PLoS ONE · 2021 · 26 citations · Full text